Approval · Notice of Compliance 335 · 2003
MAXIPIME: Notice of Compliance 335
Issued August 13, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 335
- Date
- August 13, 2003
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph update and changes to the dosage and administration section to reflect the maintenance dosing schedule for adult patients with renal impairment
- Therapeutic class
- Antibiotic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MAXIPIME | Not yet assigned | — |
Medicinal ingredients
- CEFEPIME HCL 0.5 G per VIAL
- CEFEPIME HCL 1 G per VIAL
- CEFEPIME HCL 2 G per VIAL